Aequus Pharmaceuticals Inc (TSE:AQS)
:AQS
Top Page
Aequus Pharmaceuticals
(AQS)
Select Model
Select Model
Rating:38Underperform
Price Target:
<C$0.01
▼(-10.00% Downside)
Action:ReiteratedDate:12/30/25
The score is driven primarily by weak financial fundamentals: ongoing large losses, continued cash burn, and a highly strained balance sheet with negative equity and debt exceeding assets. Technical signals provide limited support and valuation is constrained by a negative P/E and lack of dividend data.
Positive Factors
Revenue Growth
The launch of ZIMED® PF has contributed to revenue growth, indicating successful product development and market acceptance, which can enhance long-term revenue streams.
Negative Factors
Financial Instability
Persistent financial instability with declining revenues and negative net income can hinder the company's ability to invest in growth and sustain operations long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The launch of ZIMED® PF has contributed to revenue growth, indicating successful product development and market acceptance, which can enhance long-term revenue streams.
Read all positive factors
Aequus Pharmaceuticals (AQS) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$663.17K
Dividend YieldN/A
Average Volume (3M)10.00K
Price to Earnings (P/E)0.4
Beta (1Y)-3.45
Revenue Growth122.30%
EPS Growth75.74%
CountryCA
Employees12
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding132,634,430
10 Day Avg. Volume10,000
30 Day Avg. Volume10,000
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.21
Price to Sales (P/S)2.27
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aequus Pharmaceuticals Business Overview & Revenue Model
Company Description
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophtha...
How the Company Makes Money
Aequus Pharmaceuticals generates revenue primarily through the sale of its developed and commercialized pharmaceutical products, particularly in the fields of ophthalmology and transplant therapy. Key revenue streams include direct sales of brande...
Aequus Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 815.03K | 584.24K | 254.90K | 1.38M | 2.71M | 2.59M |
| Gross Profit | 433.33K | 199.97K | 143.66K | 1.15M | 2.69M | 2.59M |
| EBITDA | -1.22M | -1.79M | -2.68M | -2.87M | -1.23M | -314.80K |
| Net Income | -1.64M | -2.18M | -2.96M | -3.21M | -1.81M | -1.05M |
Balance Sheet | ||||||
| Total Assets | 236.02K | 800.28K | 1.09M | 1.69M | 4.35M | 3.13M |
| Cash, Cash Equivalents and Short-Term Investments | 35.08K | 50.24K | 170.20K | 294.67K | 2.39M | 1.72M |
| Total Debt | 6.64M | 6.61M | 5.06M | 782.92K | 2.18M | 2.32M |
| Total Liabilities | 7.51M | 7.26M | 5.38M | 3.07M | 2.56M | 2.56M |
| Stockholders Equity | -7.27M | -6.45M | -4.29M | -1.38M | 1.79M | 573.95K |
Cash Flow | ||||||
| Free Cash Flow | -443.32K | -1.66M | -2.29M | -1.95M | -1.18M | -817.23K |
| Operating Cash Flow | -443.32K | -1.66M | -2.29M | -1.95M | -1.17M | -804.91K |
| Investing Cash Flow | 44.85K | 44.85K | 0.00 | 0.00 | -507.96K | -12.32K |
| Financing Cash Flow | 389.47K | 1.49M | 2.21M | -189.19K | 2.40M | 2.05M |
Aequus Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$115.96M | 294.90 | 0.87% | ― | 2.14% | -83.06% | |
54 Neutral | C$12.73M | -2.12 | -18.39% | ― | 24.30% | -68.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$24.66M | -1.56 | -461.32% | ― | -46.59% | 8.26% | |
49 Neutral | C$4.96M | -3.46 | ― | ― | -2.30% | ― | |
39 Underperform | C$1.08M | -3.51 | 16.08% | ― | ― | 98.93% | |
38 Underperform | C$663.17K | 0.45 | 9.47% | ― | 122.30% | 75.74% |
* Healthcare Sector Average
TSE:AQS
Aequus Pharmaceuticals
0.01
0.00
0.00%
TSE:PHRX
Pharmadrug
0.01
>-0.01
-33.33%
TSE:MVMD
Mountain Valley MD
0.07
0.04
133.33%
TSE:MPH
Medicure
1.22
0.49
67.12%
TSE:MDP
Medexus Pharmaceuticals Inc
3.59
1.37
61.71%
TSE:TGIF
1933 Industries
0.01
0.00
0.00%
Aequus Pharmaceuticals Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Aequus Pharmaceuticals Clarifies Shareholder Meeting Details Amid Regulatory Disclosures
Neutral
Nov 13, 2025
Aequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, scheduled for November 21, 2025. The company clarified details about a potential share consolidation, stating it ...
Regulatory Filings and ComplianceShareholder Meetings
Aequus Pharmaceuticals Updates Shareholders on Key Meeting Details
Neutral
Nov 12, 2025
Aequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, as requested by the Ontario Securities Commission. The company clarified details about a potential share consolid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.